Masimo Co. (MASI) Given Consensus Recommendation of “Hold” by Analysts

Masimo Co. (NASDAQ:MASI) has been given an average recommendation of “Hold” by the nine brokerages that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $97.00.

MASI has been the topic of a number of research reports. Zacks Investment Research raised shares of Masimo from a “hold” rating to a “buy” rating and set a $98.00 price target on the stock in a research note on Thursday, November 2nd. Stifel Nicolaus reaffirmed a “buy” rating and issued a $108.00 price target on shares of Masimo in a research note on Friday, November 3rd. Finally, BidaskClub downgraded shares of Masimo from a “hold” rating to a “sell” rating in a research note on Thursday, December 7th.

In related news, EVP Yongsam Lee sold 5,000 shares of the company’s stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $89.89, for a total value of $449,450.00. Following the completion of the sale, the executive vice president now directly owns 74,000 shares in the company, valued at $6,651,860. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Steven Barker sold 10,000 shares of the company’s stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $90.00, for a total transaction of $900,000.00. Following the completion of the sale, the director now owns 73,249 shares of the company’s stock, valued at $6,592,410. The disclosure for this sale can be found here. Insiders sold 63,074 shares of company stock valued at $5,618,945 over the last quarter. 13.10% of the stock is currently owned by corporate insiders.

A number of large investors have recently modified their holdings of the stock. Sterling Capital Management LLC boosted its holdings in Masimo by 0.6% in the second quarter. Sterling Capital Management LLC now owns 7,803 shares of the medical equipment provider’s stock worth $711,000 after purchasing an additional 44 shares in the last quarter. Hillsdale Investment Management Inc. boosted its holdings in Masimo by 0.4% during the second quarter. Hillsdale Investment Management Inc. now owns 15,870 shares of the medical equipment provider’s stock valued at $1,447,000 after acquiring an additional 70 shares during the period. Dana Investment Advisors Inc. boosted its holdings in Masimo by 0.7% during the second quarter. Dana Investment Advisors Inc. now owns 25,594 shares of the medical equipment provider’s stock valued at $2,334,000 after acquiring an additional 185 shares during the period. Sciencast Management LP boosted its holdings in Masimo by 3.4% during the second quarter. Sciencast Management LP now owns 6,000 shares of the medical equipment provider’s stock valued at $547,000 after acquiring an additional 200 shares during the period. Finally, 1st Global Advisors Inc. boosted its holdings in Masimo by 3.2% during the second quarter. 1st Global Advisors Inc. now owns 7,468 shares of the medical equipment provider’s stock valued at $681,000 after acquiring an additional 233 shares during the period. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Masimo (NASDAQ:MASI) opened at $88.17 on Tuesday. Masimo has a one year low of $70.48 and a one year high of $104.71. The firm has a market cap of $4,560.00, a price-to-earnings ratio of 13.97, a PEG ratio of 3.39 and a beta of 0.72.

Masimo (NASDAQ:MASI) last posted its quarterly earnings results on Tuesday, October 31st. The medical equipment provider reported $0.70 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.53 by $0.17. Masimo had a net margin of 45.83% and a return on equity of 22.17%. The business had revenue of $193.69 million for the quarter, compared to the consensus estimate of $189.01 million. During the same period in the prior year, the business posted $0.52 earnings per share. Masimo’s revenue for the quarter was up 15.6% compared to the same quarter last year. equities research analysts predict that Masimo will post 2.95 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Masimo Co. (MASI) Given Consensus Recommendation of “Hold” by Analysts” was posted by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be read at https://www.americanbankingnews.com/2018/01/23/masimo-co-masi-given-consensus-recommendation-of-hold-by-analysts-2.html.

Masimo Company Profile

Masimo Corporation is a medical technology company that develops, manufactures and markets a range of non-invasive patient monitoring technologies. The Company’s business is Measure-through Motion and Low Perfusion pulse oximetry monitoring, known as Masimo Signal Extraction Technology (SET) pulse oximetry.

Analyst Recommendations for Masimo (NASDAQ:MASI)

Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply